Literature DB >> 20422500

The role of inflammation in cholestasis: clinical and basic aspects.

Astrid Kosters1, Saul J Karpen.   

Abstract

Hepatobiliary transport systems are essential for the uptake and excretion of a variety of compounds including bile acids. Disruption and dysregulation of this excretory pathway result in cholestasis, leading to the intrahepatic accumulation of bile acids and other toxic compounds with progression of liver pathology. Cholestasis induced by inflammation is a common complication in patients with extrahepatic infections or inflammatory processes, generally referred to as sepsis-associated cholestasis. Microbial products, including endotoxin, induce signaling pathways within hepatocytes either directly, or through activation of proinflammatory cytokines, leading to rapid and profound reductions in bile flow. The expression and function of key hepatobiliary transporters are suppressed in response to inflammatory signaling. These proinflammatory signaling cascades lead to repressed expression and activity of a large number of nuclear transcriptional regulators, many of which are essential for maintenance of hepatobiliary transporter gene expression. Interestingly, recently discovered molecular crosstalk between bile acid activated nuclear receptors and proinflammatory nuclear mediators may provide new means of understanding adaptive processes within liver. Inflammation-induced cholestasis and the effects of retained molecules in cholestasis on inflammatory signals are interwoven in the liver, providing potential opportunities for research and therapeutics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20422500      PMCID: PMC3746018          DOI: 10.1055/s-0030-1253227

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  98 in total

Review 1.  Hepatic hemodynamics and cell functions in human and experimental sepsis.

Authors:  C M Pastor; P M Suter
Journal:  Anesth Analg       Date:  1999-08       Impact factor: 5.108

Review 2.  Sepsis and cholestasis.

Authors:  Richard H Moseley
Journal:  Clin Liver Dis       Date:  2004-02       Impact factor: 6.126

3.  Intraabdominal sepsis down-regulates transcription of sodium taurocholate cotransporter and multidrug resistance-associated protein in rats.

Authors:  P K Kim; J Chen; K M Andrejko; C S Deutschman
Journal:  Shock       Date:  2000-08       Impact factor: 3.454

Review 4.  Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis.

Authors:  S Stahl; M R Davies; D I Cook; M J Graham
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

5.  Enhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS.

Authors:  Markus G Donner; Ulrich Warskulat; Nirmalendu Saha; Dieter Häussinger
Journal:  Biol Chem       Date:  2004 Mar-Apr       Impact factor: 3.915

6.  Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response.

Authors:  Anne P Beigneux; Arthur H Moser; Judy K Shigenaga; Carl Grunfeld; Kenneth R Feingold
Journal:  Biochem Biophys Res Commun       Date:  2002-04-26       Impact factor: 3.575

7.  Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver.

Authors:  De-Xiang Xu; Wei Wei; Mei-Fang Sun; Cheng-Yi Wu; Jian-Ping Wang; Ling-Zhen Wei; Cheng-Fan Zhou
Journal:  Free Radic Biol Med       Date:  2004-07-01       Impact factor: 7.376

8.  Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Meihua Wang; Donna Yu; Barry M Forman; Wendong Huang
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

9.  Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells.

Authors:  Kenichi Harada; Shusaku Ohira; Kumiko Isse; Satoru Ozaki; Yoh Zen; Yasunori Sato; Yasuni Nakanuma
Journal:  Lab Invest       Date:  2003-11       Impact factor: 5.662

10.  Bile salt metabolism in the first year of life.

Authors:  J E Heubi; W F Balistreri; F J Suchy
Journal:  J Lab Clin Med       Date:  1982-07
View more
  51 in total

Review 1.  Molecular mechanisms underlying chemical liver injury.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Expert Rev Mol Med       Date:  2012-02-03       Impact factor: 5.600

Review 2.  Liver - guardian, modifier and target of sepsis.

Authors:  Pavel Strnad; Frank Tacke; Alexander Koch; Christian Trautwein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

3.  Toll-like receptor 4-dependent Kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition and intestinal injury.

Authors:  Karim C El Kasmi; Aimee L Anderson; Michael W Devereaux; Sophie A Fillon; J Kirk Harris; Mark A Lovell; Milton J Finegold; Ronald J Sokol
Journal:  Hepatology       Date:  2012-03-18       Impact factor: 17.425

Review 4.  The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists.

Authors:  Ponni V Perumalswami; Thomas D Schiano
Journal:  Dig Dis Sci       Date:  2011-03-18       Impact factor: 3.199

Review 5.  NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma.

Authors:  Tom Luedde; Robert F Schwabe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

6.  Maternal liver elasticity determined by acoustic radiation force impulse elastosonography in intrahepatic cholestasis of pregnancy.

Authors:  Orkun Cetin; Erbil Karaman; Harun Arslan; Ibrahim Akbudak; Recep Yildizhan; Ali Kolusari
Journal:  J Med Ultrason (2001)       Date:  2016-12-30       Impact factor: 1.314

7.  Mesenteric panniculitis presenting as liver dysfunction.

Authors:  Kazuhiko Morii; Tomoko Hatono; Hiroaki Okushin; Takanori Watanabe; Shiso Sato; Koichi Uesaka; Shiro Yuasa
Journal:  Clin J Gastroenterol       Date:  2011-12-20

8.  Dominant-negative NFKBIA mutation promotes IL-1β production causing hepatic disease with severe immunodeficiency.

Authors:  Enrica Ek Tan; Richard A Hopkins; Chrissie K Lim; Saumya S Jamuar; Christina Ong; Koh C Thoon; Mark Ja Koh; Eun Mong Shin; Derrick Wq Lian; Madhushanee Weerasooriya; Christopher Zw Lee; Andreas Alvin Pumomo Soetedjo; Chang Siang Lim; Veonice B Au; Edmond Chua; Hui Yin Lee; Leigh Ann Jones; Sharmy S James; Nivashini Kaliaperumal; Jeffery Kwok; Ee Shien Tan; Biju Thomas; Lynn Xue Wu; Lena Ho; Anna Marie Fairhurst; Florent Ginhoux; Adrian Kk Teo; Yong Liang Zhang; Kok Huar Ong; Weimiao Yu; Byrappa Venkatesh; Vinay Tergaonkar; Bruno Reversade; Keh Chuang Chin; Ah Moy Tan; Woei Kang Liew; John E Connolly
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 9.  Impact of new-generation lipid emulsions on cellular mechanisms of parenteral nutrition-associated liver disease.

Authors:  Douglas G Burrin; Ken Ng; Barbara Stoll; Miguel Sáenz De Pipaón
Journal:  Adv Nutr       Date:  2014-01-01       Impact factor: 8.701

10.  Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition-associated liver disease.

Authors:  Karim C El Kasmi; Aimee L Anderson; Michael W Devereaux; Padade M Vue; Wujuan Zhang; Kenneth D R Setchell; Saul J Karpen; Ronald J Sokol
Journal:  Sci Transl Med       Date:  2013-10-09       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.